Searched for
PATENTED DRUGS PRICING
Over 1,300 anti-cancer drugs to get cheaperIndia's National Pharmaceutical Pricing Authority is set to cap trade margins on anti-cancer drugs starting November 2026. The initiative a...- Cancer drug prices revised from today; patients may save Rs 3,540 crore annuallyThe government has revised the prices of 1,364 anti-cancer medicine formulations effective from November 9. This decision aims to limit tra...
- Wockhardt seeks 14-year data shield for India-made drugsMumbai-based Wockhardt has struck success in its innovative research on a range of antibiotic drugs, bridging a global pipeline gap for dif...
- Cancer drug prices fell in 2019 too, but mark-ups of up to 700% are backThe government's latest cancer drug price cuts may offer patients some relief, but the impact could be short-lived. An analysis of medicine...
- NPPA list brings little relief: No price cut for 25% cancer drugsNearly one in four cancer drug packs in the NPPA’s revised price list will see no reduction in MRP, even as the overall average cut across ...
- Cancer drug price cuts leave costly brands untouchedPrices of several anti-cancer drugs are set to fall significantly starting November 9, offering some financial relief. However, the prices ...
- Cancer care can be cheaper: 6 steps to cut drug costsIndia has capped trade margins at 30% on 137 non-scheduled anti-cancer drugs to reduce treatment costs. Experts call for standardised care,...
- GLP-1 boom in China, India, Brazil could create $22 billion market by 2035, J.P. Morgan saysThe China-India-Brazil market for GLP-1 weight-loss drugs could expand to $22 billion by 2035 from $6.6 billion currently, J.P. Morgan esti...
- Sahajanand Medical Technologies shares list at 8% premium over IPO price on NSEThe Rs 475.48 crore IPO comprised an offer for sale (OFS) of 1.38 crore shares. Since the issue was entirely an OFS, the company will not r...
- Sahajanand Medical Technologies IPO Day 3: GMP at 7%; check subscription status and key detailsSahajanand Medical Technologies’ IPO enters its final bidding day with 82% subscription on Day 2 and a 7% grey market premium. The Rs 475.4...
- The burden of cancer drugs: Millions battle exorbitant prices as life-saving treatment slips out of reachFor millions of cancer patients, the cost of treatment can be as frightening as the diagnosis. From steep markups to patented drugs that re...
- Sahajanand Medical Technologies IPO Day 2: Check GMP, subscription status and key detailsSahajanand Medical Technologies IPO entered Day 2 on October 16, 2026, with a 12% GMP and 34% subscription on Day 1. The Rs 475.48-crore of...
- Sahajanand Medical Technologies IPO opens for subscription. Check GMP, price band and key detailsSahajanand Medical Technologies IPO opened for subscription on October 15, 2026, aiming to raise Rs 475.48 crore through an entirely offer-...
- Protect patients and patents smartlyThe Kerala High Court has stressed the importance of making cancer medicines like ribociclib more affordable for patients. The Government o...
- Panel to finalise cancer drugs for 30% trade margin cap; Rs 2,500 crore annual savings possibleAn expert group is finalizing the list of cancer medicines for a new trade margin cap. The government plans to implement a 30% cap to reduc...
- Cancer drugs may get up to 70% cheaper as govt fixes trade margins on non-scheduled medicines at 30%The government is aiming to cap trade margins on anti-cancer medications at 30%. An expert committee has been tasked with compiling a repor...
- ‘India’s biotech ecosystem holds tremendous promise’: Eli Lilly CEOEli Lilly has experienced significant growth, reaching a market capitalization over $1 trillion. The company aims to maintain its leadershi...
- Women tip the scale as weight-loss boom reaches tier-II citiesWhile startups such as General Catalyst-backed Voy and Mumbai-based Metago are seeing higher demand from women, Elevate Now, backed by Tita...
- Kerala HC says exorbitant drug prices can trigger government intervention in patented medicinesThe Kerala High Court ruled that government intervention is permissible for prohibitively priced patented medicines. The court directed the...
- Rs 78,400 vs Rs 7,750 medicine: Novartis, Eli Lilly oppose bid to cut breast cancer drug prices in IndiaNovartis and Eli Lilly have opposed a Kerala High Court petition seeking government intervention to make two breast cancer drugs cheaper, d...
Load More
